Taken together, these results suggest that MG1 in combination with αPD-1 may be an effective treatment option particularly for more advanced melanoma, with partial reversal of the immunosuppressive microenvironment in larger tumors being boosted by the addition of ICI to reveal a therapeutic effect. The gene discussed is MUC5B; the disease is melanoma.